What is the Glutathione Patch
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
The cellular mechanics of cardiorespiratory fitness: mitochondria, lactate, muscle fiber recruitment, and intensity thresholds [18:45]
Unreconstituted vials: Store in a cool, dry place or refrigerator
Only 4.2% of participants discontinued due to side effects after week 24, indicating that side effects become manageable or resolve entirely for the vast majority who continue treatment